Navigation Links
Drug Development Program Started Based on CAP(R) Human Cell Line
Date:3/3/2009

COLOGNE, Germany, March 3 /PRNewswire/ --

- New Platform May Provide Solutions for Many RA-Patients Around the World

Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The Netherlands) announce the start of Theraptech, a 2.4 million Euro therapeutic protein development program subsidized under the European Trans Bio Program. The major objective of the Theraptech project is to develop a recombinant human alkaline phosphatase (rhuAP) using the novel versatile human CAP(R) cell line, which has been shown to efficiently express glycosylated proteins. The rhuAP produced in CAP(R) cells is expected to feature improved pharmacokinetic and safety profile allowing for repeated dosing of alkaline phosphatase in chronic diseases. Based on a the anti-inflammatory mechanism of action of alkaline phosphatase towards e.g. TNFa, IL-6 and IL-8, as shown in both pre-clinical and clinical studies in acute conditions, we propose it to be developed as a therapeutic protein in major chronic diseases such as Rheumatoid Arthritis. The combined expertise of the members participating in the consortium covers the entire spectrum of activities needed to drive the project from molecular biology to GMP-production and recombinant product testing in preclinical and clinical trials, pushing towards a clinical phase II compliant product within the 3-year-time frame of the project.

Commenting on this unique co-operation, PharmaCell's CEO, Maurice Horsten, commented "Combining the strengths of our companies provides us with an excellent opportunity to build on PharmaCell's motto Humanizing Medicine(R) and to push this important project forward to the benefit of many patients around the world."

Cevec's CEO Dr Rainer Lichtenberger added: "CEVEC is excited about the strong scientific and commercial prospects of the Theraptech project. rhuAP will turn out to perfectly demonstrate the unique strengths of CEVEC's proprietary CAP(R) cell expression technology, in combination with the proven capabilities of our partners."

On the scientific importance Alloksys' COO, Dr Ruud Brands commented: "rhuALP, based on the proposed mechanism of action in innate immune modulation, may enable the application in a wide array of disabling chronic inflammatory conditions, thereby eliminating the potentially adverse effects of currently marketed blockbuster products."

About Alloksys Life Sciences BV -http://www.alloksys.eu

Alloksys Life Sciences BV, established in 2005 and located in Bunnik, The Netherlands is a biopharmaceutical company dedicated to the R&D of therapeutic proteins for the treatment of both acute and chronic inflammatory diseases. The lead phase II compound bIAP, an innate-immune system-modulating compound is developed for the indication: prevention of ischemia-reperfusion damage in invasive surgery. Chronic applications atherosclerosis, rheumatoid arthritis, Alzheimers and asthma are targeted. Alloksys established an integral research network comprising of several academic and biotech collaborations, both nationally and internationally. Partnerships with pharmaceutical companies for co-development of these indications are welcomed.

About CEVEC Pharmaceuticals GmbH - http://www.cevec-pharmaceuticals.com

CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP(R) and CAP-T(TM) expression systems are ideal for manufacturing complex biopharmaceutical molecules. CEVEC is licensing out its human cell-based expression platform as well as the biological product candidates in internal development through partnerships with renowned pharmaceutical and biotech companies.

About PharmaCell - http://www.pharmacell.nl

PharmaCell provides contract services in the area of human cell & tissue banking & culturing as well as human cell line development and manufacturing of (bio) pharmaceuticals. Next to a GMP license, PharmaCell is the only commercial company in The Netherlands to hold an official license as Registered Tissue Establishment.

PharmaCell is also actively engaged in Research & Development work, both on behalf of some of its customers as well as in research consortia together with Universities, Academic Hospitals and other (bio)tech companies.

    Contact:
    CEVEC Pharmaceuticals GmbH
    Dr. Rainer Lichtenberger, CEO
    Gottfried-Hagen-Str. 62
    51105 Koln, Germany
    Tel: +49-221-46-02-08-10
    Fax: +49-221-46-02-08-01
    Mail: lichtenberger@cevec-pharmaceuticals.com

   http://www.cevec-pharmaceuticals.com


'/>"/>
SOURCE CEVEC Pharmaceuticals GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Promising Cystic Fibrosis Compound on Track for Development
3. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
8. Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
9. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
10. EntreMed Raises $20 Million to Support Clinical Development Program
11. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):